Stay updated on Efgartigimod Safety & Efficacy in pSS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.

Latest updates to the Efgartigimod Safety & Efficacy in pSS Clinical Trial page
- Check6 days agoChange DetectedIQVIA Pty Ltd was added as a collaborator and Iqvia Pty Ltd was removed.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated to v3.5.0; previous revision v3.4.3 was removed.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page now displays Revision: v3.4.3 in the footer, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check64 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2, representing a minor update with no impact on study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check71 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1; this is a metadata/version control change and does not modify study content or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check78 days agoChange DetectedAdded a glossary display and a new QC-related metadata label (Last Update Submitted that Met QC Criteria) with a revision reference (v3.4.0), and adjusted capitalization of No FEAR Act data across the page.SummaryDifference0.2%

Stay in the know with updates to Efgartigimod Safety & Efficacy in pSS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.